Abcam, ab312849, Anti-DR4 antibody [EPR28152-57] - BSA and Azide free

Size: 100µg / 1mg
Knockout Tested Rabbit Recombinant Monoclonal DR4 antibody. Carrier free. Suitable for ICC/IF, WB, Flow Cyt (Intra) and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR28152-57,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, Flow Cyt (Intra), ICC/IFSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:This antibody does not cross react with DR5 and DcR2.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
DR4 also known as TRAIL-R1 is a receptor with a molecular weight of approximately 60 kDa. It is part of the tumor necrosis factor receptor (TNFR) superfamily. DR4 is widely expressed in various types of tissues such as the liver spleen thymus and peripheral blood leukocytes. It functions mechanically by binding to its ligand TNF-related apoptosis-inducing ligand (TRAIL) which initiates signaling cascades that lead to apoptosis or programmed cell death.
Biological function summary
The death receptor 4 plays an important role in mediating cell apoptosis. Upon ligand binding DR4 interacts with the adapter molecule FADD (FAS-associated protein with death domain) facilitating the formation of the death-inducing signaling complex (DISC). This complex recruits and activates caspase-8 which eventually leads to the activation of the downstream effector caspases driving the cell towards apoptosis. DR4 operates as a significant component of the extrinsic pathway of apoptosis a process important for maintaining cellular homeostasis and eliminating harmful cells.
Pathways
DR4 functions critically within the extrinsic apoptotic pathway. This pathway involves other death receptors such as DR5 which also binds TRAIL similarly leading to apoptosis through DISC formation and caspase activation. The extrinsic pathway interconnects with the intrinsic pathway via the mitochondria with proteins like Bid acting as a bridge between them. The engagement of these pathways highlights DR4’s importance in regulatory mechanisms of cell death tightly controlling cellular proliferation and survival.
DR4 plays a significant role in cancer and autoimmune diseases. Alterations in DR4 expression or function can lead to evasion of apoptosis by cancer cells contributing to tumor progression. The defective apoptotic signaling via DR4 is also linked to autoimmune disorders where insufficient apoptosis may allow for the survival of autoreactive immune cells. In both scenarios DR4's involvement usually associates with its counterpart DR5 as they share similar ligand-binding properties and signal transduction mechanisms in diseased states.